etidronate has been researched along with Necrosis in 9 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
Necrosis: The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral etidronate has been used for 3 weeks, after failure of classical treatment." | 5.34 | [Etidronate per os in subcutaneous fat necrosis with hypercalcemia and nephrocalcinosis]. ( Bottu, J; Trullemans, B; Van Nieuwenhuyse, JP, 2007) |
| "These results suggest that etidronate may 1) inhibit the entry of NBPs into cells related to inflammation and/or necrosis, 2) inhibit the binding of NBPs to bone hydroxyapatite, 3) at least partly eliminate (or substitute for) NBPs that have already accumulated within bones, and thus 4) if used as a substitution drug for NBPs, be effective at treating or preventing NBP-associated osteonecrosis of the jaw." | 3.76 | Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs. ( Endo, Y; Funayama, H; Kawamura, H; Kumamoto, H; Kuroishi, T; Oizumi, T; Sasaki, K; Sugawara, S; Takahashi, H; Yamaguchi, K; Yamamoto, M; Yokoyama, M, 2010) |
| "Oral etidronate has been used for 3 weeks, after failure of classical treatment." | 1.34 | [Etidronate per os in subcutaneous fat necrosis with hypercalcemia and nephrocalcinosis]. ( Bottu, J; Trullemans, B; Van Nieuwenhuyse, JP, 2007) |
| "This osteolysis was evaluated by measuring the increased area of bone resorption in reduced opacity to radiograph and histologic study." | 1.28 | Inhibition by a new bisphosphonate (AHBuBP) of bone resorption induced by the MBT-2 tumor of mice. ( Koiso, K; Miyagawa, I; Nemoto, R; Satou, S, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (44.44) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Okada, S | 1 |
| Kiyama, T | 1 |
| Sato, E | 1 |
| Tanaka, Y | 1 |
| Oizumi, T | 2 |
| Kuroishi, T | 2 |
| Takahashi, T | 1 |
| Sasaki, K | 2 |
| Sugawara, S | 2 |
| Endo, Y | 2 |
| Funayama, H | 1 |
| Yamaguchi, K | 1 |
| Yokoyama, M | 1 |
| Takahashi, H | 1 |
| Yamamoto, M | 1 |
| Kumamoto, H | 1 |
| Kawamura, H | 1 |
| Trullemans, B | 1 |
| Bottu, J | 1 |
| Van Nieuwenhuyse, JP | 1 |
| Caldecourt, MA | 1 |
| Cole, AW | 1 |
| Kingaby, RO | 1 |
| Palmer, TN | 1 |
| Hughes, DE | 1 |
| Wright, KR | 1 |
| Uy, HL | 1 |
| Sasaki, A | 1 |
| Yoneda, T | 1 |
| Roodman, GD | 1 |
| Mundy, GR | 1 |
| Boyce, BF | 1 |
| Creutzig, H | 1 |
| Schulz, D | 1 |
| Nemoto, R | 1 |
| Satou, S | 1 |
| Miyagawa, I | 1 |
| Koiso, K | 1 |
| Daoud, AS | 1 |
| Frank, AS | 1 |
| Jarmolych, J | 1 |
| Fritz, KE | 1 |
| Raper, RF | 1 |
| Ibels, LS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 other studies available for etidronate and Necrosis
| Article | Year |
|---|---|
Inhibition of phosphate transporters ameliorates the inflammatory and necrotic side effects of the nitrogen-containing bisphosphonate zoledronate in mice.
Topics: Animals; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Foscarnet; Imidazo | 2013 |
Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Ear, Extern | 2010 |
[Etidronate per os in subcutaneous fat necrosis with hypercalcemia and nephrocalcinosis].
Topics: Adipose Tissue; Calcinosis; Etidronic Acid; Female; Humans; Hypercalcemia; Infant; Kidney Diseases; | 2007 |
Liposome accumulation in chronic ischaemia is dependent on tissue necrosis.
Topics: Animals; Etidronic Acid; Hydrocortisone; Intestines; Ischemia; Liposomes; Male; Necrosis; Pharmaceut | 1984 |
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo.
Topics: Animals; Apoptosis; Bone Neoplasms; Cell Survival; Cells, Cultured; Diphosphonates; Etidronic Acid; | 1995 |
[Comparative studies with bone-seeking radiopharmaceuticals on uptake in necrotic tissue].
Topics: Animals; Diphosphonates; Etidronic Acid; Indium; Male; Muscles; Necrosis; Organophosphorus Compounds | 1977 |
Inhibition by a new bisphosphonate (AHBuBP) of bone resorption induced by the MBT-2 tumor of mice.
Topics: Alendronate; Animals; Diphosphonates; Etidronic Acid; Female; Mice; Mice, Inbred C3H; Necrosis; Neop | 1991 |
The effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) on necrosis of atherosclerotic lesions.
Topics: Animals; Aorta, Abdominal; Arteriosclerosis; Calcium; Cholesterol; Diet, Atherogenic; DNA; Etidronic | 1987 |
Osteosclerotic myeloma complicated by diffuse arteritis, vascular calcification and extensive cutaneous necrosis.
Topics: Adult; Aluminum Hydroxide; Arteritis; Bone Neoplasms; Calcinosis; Cyclophosphamide; Etidronic Acid; | 1985 |